Podocan and Wnt Pathway in Left Ventricular Remodeling of Aortic Stenosis
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/23/2019 |
| Start Date: | October 2015 |
| End Date: | December 2019 |
Clinical Predictive Value of Podocan and Wnt Pathway Regulatory Molecules on Maladaptive Left Ventricular Response in Aortic Stenosis
Aortic stenosis is a major cause of morbidity around the world. Progressive aortic stenosis
leads to cardiac hypertrophy as a compensatory response. A maladaptive response may lead to
heart failure at varying degrees of severity of aortic stenosis in individual patients. The
predicting factors for the occurrence of a maladaptive response are not well defined.
Therefore current medical therapy for aortic stenosis is considered insufficient and may
actually cause harm. The only effective therapy for severe, symptomatic aortic stenosis is
aortic valve replacement. It has been found in an experimental study that Podocan determines
the degree of cardiac hypertrophy in response to pressure overload via the Wnt-pathway. The
possible prognostic role of secreted circulating Wnt modulators in aortic stenosis has also
recently gained attention. This project will attempt to establish the prognostic role of
circulatory Podocan and Wnt modulators for maladaptive left ventricular response to aortic
stenosis. This may help identify patients at particular risk to develop left ventricular
dysfunction with aortic stenosis and improve understanding of the mechanisms of left
ventricular remodeling in aortic stenosis. Hence, this may also later act as an important
background in finding more effective therapies to prevent or delay maladaptive left
ventricular response in aortic stenosis.
leads to cardiac hypertrophy as a compensatory response. A maladaptive response may lead to
heart failure at varying degrees of severity of aortic stenosis in individual patients. The
predicting factors for the occurrence of a maladaptive response are not well defined.
Therefore current medical therapy for aortic stenosis is considered insufficient and may
actually cause harm. The only effective therapy for severe, symptomatic aortic stenosis is
aortic valve replacement. It has been found in an experimental study that Podocan determines
the degree of cardiac hypertrophy in response to pressure overload via the Wnt-pathway. The
possible prognostic role of secreted circulating Wnt modulators in aortic stenosis has also
recently gained attention. This project will attempt to establish the prognostic role of
circulatory Podocan and Wnt modulators for maladaptive left ventricular response to aortic
stenosis. This may help identify patients at particular risk to develop left ventricular
dysfunction with aortic stenosis and improve understanding of the mechanisms of left
ventricular remodeling in aortic stenosis. Hence, this may also later act as an important
background in finding more effective therapies to prevent or delay maladaptive left
ventricular response in aortic stenosis.
Valvular heart disease is a common clinical indication to assess patients with cardiac MRI.
Cardiac MRI is comprehensive study that uses multiple imaging sequences.Cardiac MRI is
indicated to image native and prosthetic aortic valves. Planimetry of the aortic valve is
valuable for determination of the severity of aortic stenosis. Cardiac MRI is the most
accurate and reproducible imaging modality to assess left ventricular function and mass. Left
ventricular (LV) function is a primary determinant of outcomes following aortic valve
replacement. LV mass is increased in severe aortic stenosis. Variations in the morphology of
hypertrophy in response to aortic stenosis have been detected by cardiac MRI. Cardiac MRI is
commonly used to assess aortic stenosis in the context of discordant information from
alternative imaging modalities and low gradient aortic stenosis.
It is expected that 100 participants will be enrolled in the study over 24 months. This is
sample size was agreed upon after discussion with the statistics team.
Patients who agree to participate will provide informed consent prior to their cardiac MRI. A
6 minute walk test to measure baseline functional status will be done after consent,
preferably just prior to reporting to the MRI suite for their scheduled test. Standard
cardiac MRI will be obtained. All patients having a cardiac MRI have an IV line placed as
normal procedure. When the line has been placed, prior to contrast infusion (if applicable)or
other medication administration, blood samples will be collected to test for circulatory
Podocan and Wnt pathway molecules. Approximately 20 cc will be drawn in total. All specimens
will be sent to the experimental lab of Dr. Paul Klotman at Baylor Medical Center. All of the
Podocan & Wnt pathway effectory molecules assays will be completed by Dr. Klotman's lab.
The following measurements will be collected from the cardiac MRI:
LV end diastolic (ED) volume: ml LV ED index: ml/m2 LV end systolic (ES) volume: ml LV ES
index: ml/m2 LV ejection fraction (EF): % LV Stroke Volume: ml LV Stroke Index: ml/m2 LV
Cardiac Output: L/min LV Cardiac Index: L/min/M2 LV Mass: g LV Mass index: g/m2
At 12 months post procedure the following information will be collected from the
participants' charts for endpoint analysis:
All cause mortality Cardiac mortality Hospital admissions for valvular disease related
clinical events such as congestive heart failure, angina, syncope Valve replacement surgery
Patients who do undergo valve replacement surgery during the 12 month follow up period and
are scheduled to undergo a post-op follow up cardiac MRI (expected to be at 9-12 months
post-op) will be asked to provide additional blood samples to test for circulatory Podocan
and Wnt pathway molecules at the time of the MRI.
Each participant's chart will be reviewed at the time of enrollment and the following
variables will be abstracted from the medical record:
age, gender, ethnicity, Most recent Ht, Wt, BP, Heart Rate BMI Tobacco use/history Alcohol
use/ history Comorbidities
- Hypertension
- Hyperlipidemia
- Diabetes
- Chronic Kidney Disease
- Cancer
- CAD
Info from previous echocardiogram:
- Ejection fraction
- Valve area
- Gradient
Info from previous cardiac cath (if done):
- Presence/absence of coronary stenosis
- Location & degree of stenosis
- Aortic valve area
- Calculation of valve area
Info from previous ECG:
- Rhythm
- Left Ventricular Hypertrophy Medications
Laboratory data:
- Lipids
- Chemistries
- Complete Blood Count
- Hemoglobin A1C
- Troponin
- B-type Natriuretic Peptide
Cardiac MRI is comprehensive study that uses multiple imaging sequences.Cardiac MRI is
indicated to image native and prosthetic aortic valves. Planimetry of the aortic valve is
valuable for determination of the severity of aortic stenosis. Cardiac MRI is the most
accurate and reproducible imaging modality to assess left ventricular function and mass. Left
ventricular (LV) function is a primary determinant of outcomes following aortic valve
replacement. LV mass is increased in severe aortic stenosis. Variations in the morphology of
hypertrophy in response to aortic stenosis have been detected by cardiac MRI. Cardiac MRI is
commonly used to assess aortic stenosis in the context of discordant information from
alternative imaging modalities and low gradient aortic stenosis.
It is expected that 100 participants will be enrolled in the study over 24 months. This is
sample size was agreed upon after discussion with the statistics team.
Patients who agree to participate will provide informed consent prior to their cardiac MRI. A
6 minute walk test to measure baseline functional status will be done after consent,
preferably just prior to reporting to the MRI suite for their scheduled test. Standard
cardiac MRI will be obtained. All patients having a cardiac MRI have an IV line placed as
normal procedure. When the line has been placed, prior to contrast infusion (if applicable)or
other medication administration, blood samples will be collected to test for circulatory
Podocan and Wnt pathway molecules. Approximately 20 cc will be drawn in total. All specimens
will be sent to the experimental lab of Dr. Paul Klotman at Baylor Medical Center. All of the
Podocan & Wnt pathway effectory molecules assays will be completed by Dr. Klotman's lab.
The following measurements will be collected from the cardiac MRI:
LV end diastolic (ED) volume: ml LV ED index: ml/m2 LV end systolic (ES) volume: ml LV ES
index: ml/m2 LV ejection fraction (EF): % LV Stroke Volume: ml LV Stroke Index: ml/m2 LV
Cardiac Output: L/min LV Cardiac Index: L/min/M2 LV Mass: g LV Mass index: g/m2
At 12 months post procedure the following information will be collected from the
participants' charts for endpoint analysis:
All cause mortality Cardiac mortality Hospital admissions for valvular disease related
clinical events such as congestive heart failure, angina, syncope Valve replacement surgery
Patients who do undergo valve replacement surgery during the 12 month follow up period and
are scheduled to undergo a post-op follow up cardiac MRI (expected to be at 9-12 months
post-op) will be asked to provide additional blood samples to test for circulatory Podocan
and Wnt pathway molecules at the time of the MRI.
Each participant's chart will be reviewed at the time of enrollment and the following
variables will be abstracted from the medical record:
age, gender, ethnicity, Most recent Ht, Wt, BP, Heart Rate BMI Tobacco use/history Alcohol
use/ history Comorbidities
- Hypertension
- Hyperlipidemia
- Diabetes
- Chronic Kidney Disease
- Cancer
- CAD
Info from previous echocardiogram:
- Ejection fraction
- Valve area
- Gradient
Info from previous cardiac cath (if done):
- Presence/absence of coronary stenosis
- Location & degree of stenosis
- Aortic valve area
- Calculation of valve area
Info from previous ECG:
- Rhythm
- Left Ventricular Hypertrophy Medications
Laboratory data:
- Lipids
- Chemistries
- Complete Blood Count
- Hemoglobin A1C
- Troponin
- B-type Natriuretic Peptide
Inclusion Criteria:
- Age 18 or greater
- Scheduled for Cardiac MRI
- Patients with known aortic valve area of less than 1 cm² on echocardiogram
- Able to provide informed consent
- Ambulatory and expected to be able to complete 6 minute walk test
Exclusion Criteria:
- Other significant (moderate or severe) valvular heart disease
- Unable to complete 6 minute walk test (ex. Wheelchair bound)
We found this trial at
1
site
Cooperstown, New York 13326
Principal Investigator: Daniel Katz, MD
Phone: 607-547-6965
Click here to add this to my saved trials
